A Changing Pharmaceutical Industry
The massive development of genetics and biotechnology is getting the pharmaceutical industry to step up to a real shift in its industrial model. The blockbusters’ economic model – based on mass consumption – is indeed increasingly moving towards a more fragmented model, grounded on target groups.
In this framework, development of new therapies is more and more relying on newly created, small or medium-sized organizations. A large part of these new players opt for innovative therapeutics and personalized medicine strategies, based on specific and rare expertise such as genetics, molecular biology or cell culture. While having a strong scientific expertise, these organizations face hurdles in their transition from basic or preclinical research to clinical development, and then again from first marketing authorization to accessing markets worldwide.
Outsourcing of clinical research and development, regulatory, market access, or business development functions represents, in that case, a high added value for such organizations. Such a strategy allows companies to bring the needed clinical development and business development skills while controlling costs and deadlines.